Landscape Capital Management L.L.C. purchased a new position in Doximity, Inc. (NYSE:DOCS – Free Report) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 32,836 shares of the company’s stock, valued at approximately $931,000.
A number of other hedge funds also recently bought and sold shares of the business. HighTower Advisors LLC lifted its holdings in shares of Doximity by 1.0% in the 3rd quarter. HighTower Advisors LLC now owns 37,067 shares of the company’s stock valued at $1,050,000 after acquiring an additional 352 shares during the last quarter. Signaturefd LLC increased its position in shares of Doximity by 10.4% during the 3rd quarter. Signaturefd LLC now owns 4,205 shares of the company’s stock valued at $119,000 after purchasing an additional 397 shares during the last quarter. Allworth Financial LP raised its holdings in Doximity by 29.3% during the 3rd quarter. Allworth Financial LP now owns 2,642 shares of the company’s stock valued at $75,000 after buying an additional 599 shares during the period. Nisa Investment Advisors LLC lifted its position in Doximity by 59.9% in the third quarter. Nisa Investment Advisors LLC now owns 1,855 shares of the company’s stock worth $53,000 after buying an additional 695 shares during the last quarter. Finally, Apella Capital LLC boosted its stake in Doximity by 1.4% during the third quarter. Apella Capital LLC now owns 59,488 shares of the company’s stock worth $1,647,000 after buying an additional 802 shares during the period. Hedge funds and other institutional investors own 87.19% of the company’s stock.
Analyst Upgrades and Downgrades
Several analysts have issued reports on DOCS shares. Canaccord Genuity Group raised their price objective on shares of Doximity from $36.00 to $40.00 and gave the stock a “buy” rating in a research note on Friday, November 6th. Wolfe Research upgraded Doximity to an “outperform” rating in a research report on Thursday, August 13th. Needham & Company LLC reaffirmed a “buy” rating and issued a $41.00 price target on shares of Doximity in a research note on Friday, November 6th. Stifel Nicolaus set a $27.00 price objective on Doximity in a research note on Tuesday, September 8th. Finally, BMO Capital Markets reaffirmed a “market perform” rating and set a $30.00 target price on shares of Doximity in a research report on Friday, August 7th. Eight equities research analysts have rated the stock with a Buy rating, fourteen have issued a Hold rating and three have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Doximity currently has a consensus rating of “Hold” and a consensus target price of $30.59.
View Our Latest Research Report on Doximity
Insider Transactions at Doximity
In other news, CAO Siddharth Sitaram sold 2,613 shares of the firm’s stock in a transaction dated Wednesday, October 14th. The stock was sold at an average price of $30.68, for a total value of $80,166.84. Following the completion of the transaction, the chief accounting officer directly owned 101,432 shares in the company, valued at $3,111,933.76. This trade represents a 2.51% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Phoebe Yang sold 1,290 shares of the company’s stock in a transaction that occurred on Wednesday, September 30th. The shares were sold at an average price of $26.71, for a total value of $34,455.90. Following the completion of the sale, the director owned 24,744 shares in the company, valued at approximately $660,912.24. This represents a 4.96% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 25,224 shares of company stock valued at $801,442 in the last quarter. Insiders own 31.80% of the company’s stock.
Doximity Stock Down 3.4%
NYSE:DOCS opened at $29.64 on Friday. The firm has a 50 day moving average of $30.23 and a 200 day moving average of $25.19. Doximity, Inc. has a 52 week low of $17.15 and a 52 week high of $51.85. The stock has a market capitalization of $5.29 billion, a price-to-earnings ratio of 41.16, a PEG ratio of 32.84 and a beta of 1.29.
Doximity (NYSE:DOCS – Get Free Report) last announced its earnings results on Thursday, November 5th. The company reported $0.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.19 by $0.17. Doximity had a return on equity of 15.80% and a net margin of 21.12%. The company had revenue of $174.54 million for the quarter. During the same period in the prior year, the company earned $0.45 earnings per share. The company’s quarterly revenue was up 3.6% on a year-over-year basis. As a group, analysts expect that Doximity, Inc. will post 0.72 EPS for the current year.
Doximity Company Profile
Doximity, Inc. operates a digital platform designed for medical professionals, including physicians and other clinicians. Its services support professional networking, medical news and research discovery, career development, and communication among healthcare professionals. The company also offers clinical workflow tools, including Doximity Dialer, which enables clinicians to make calls and conduct video visits using a work number, as well as digital fax and document services. Doximity provides marketing and recruitment solutions to healthcare organizations and life sciences companies.
Featured Articles
- Five stocks we like better than Doximity
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for Doximity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Doximity and related companies with MarketBeat.com's FREE daily email newsletter.
